{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:03:46Z","timestamp":1784347426539,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106855","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:44:17Z","timestamp":1762962257000},"page":"106855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Why the disease modifying therapy transition? Investigating the reasons and clinical consequences in multiple sclerosis"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6499-1523","authenticated-orcid":false,"given":"Darin T.","family":"Okuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom G.","family":"Punnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatum M.","family":"Moog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy W.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter V.","family":"Sguigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Tardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanan B.","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan C.","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2025.106855_bib0038","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamaneurol.2019.2399","article-title":"Association of chronic active multiple sclerosis lesions with disability In Vivo","volume":"76","author":"Absinta","year":"2019","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.msard.2025.106855_bib0005","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jamaneurol.2021.3416","article-title":"Health disparities, inequities, and social determinants of Health in Multiple sclerosis and related disorders in the US: a review","volume":"78","author":"Amezcua","year":"2021","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106855_bib0031","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s40120-022-00404-1","article-title":"Persistence, adherence, and switching to higher-cost therapy in patients with multiple sclerosis initiating oral disease-modifying therapies: a retrospective real-world study","volume":"11","author":"Araujo","year":"2022","journal-title":"Neurol. Ther."},{"issue":"3","key":"10.1016\/j.msard.2025.106855_bib0035","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1212\/NXI.0000000000000102","article-title":"Early CNS neurodegeneration in radiologically isolated syndrome","volume":"2","author":"Azevedo","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"18","key":"10.1016\/j.msard.2025.106855_bib0002","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000200150","article-title":"The economic burden of multiple sclerosis in the United States: estimate of direct and indirect costs","volume":"98","author":"Bebo","year":"2022","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2025.106855_bib0037","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ana.26281","article-title":"Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis","volume":"91","author":"Bischof","year":"2022","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106855_bib0025","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1212\/WNL.0000000000002904","article-title":"US health insurance is an obstacle to disease-modifying treatments in MS","volume":"87","author":"Bourdette","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2025.106855_bib0010","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1007\/s12325-020-01367-1","article-title":"Treatment patterns among patients with multiple sclerosis initiating second-line disease-modifying therapy","volume":"37","author":"Bowen","year":"2020","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.msard.2025.106855_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191646","article-title":"Socio-economic status influences access to second-line disease modifying treatment in relapsing remitting Multiple Sclerosis patients","volume":"13","author":"Calocer","year":"2018","journal-title":"PLoS One."},{"issue":"3","key":"10.1016\/j.msard.2025.106855_bib0040","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/brain\/awaa436","article-title":"Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI","volume":"144","author":"Dal-Bianco","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106855_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103474","article-title":"The association between deprivation and the access to disease modifying therapies for multiple sclerosis: an England wide community-based study in the UK MS Register","volume":"57","author":"Das","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106855_bib0020","first-page":"263","article-title":"Patient perceptions of multiple sclerosis and its treatment","volume":"6","author":"de Seze","year":"2012","journal-title":"Patient Prefer. Adherence."},{"issue":"5","key":"10.1016\/j.msard.2025.106855_bib0033","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1750-3639.2010.00401.x","article-title":"Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis","volume":"20","author":"Dziedzic","year":"2010","journal-title":"Brain. Pathol."},{"issue":"4","key":"10.1016\/j.msard.2025.106855_bib0016","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40801-023-00387-x","article-title":"Treatment patterns by race and ethnicity in newly diagnosed persons with multiple sclerosis","volume":"10","author":"Geiger","year":"2023","journal-title":"Drugs Real. World. Outcomes"},{"key":"10.1016\/j.msard.2025.106855_bib0036","article-title":"Cerebellar volume loss in radiologically isolated syndrome","author":"George","year":"2019","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106855_bib0039","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ana.26657","article-title":"Positron emission tomography with [(18) F]-DPA-714 unveils a smoldering component in most multiple sclerosis lesions which drives disease progression","volume":"94","author":"Hamzaoui","year":"2023","journal-title":"Ann. Neurol."},{"issue":"21","key":"10.1016\/j.msard.2025.106855_bib0024","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1212\/WNL.0000000000001608","article-title":"The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?","volume":"84","author":"Hartung","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2025.106855_bib0026","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1377\/hlthaff.2018.05357","article-title":"Trends In coverage for disease-modifying therapies for multiple sclerosis In Medicare part D","volume":"38","author":"Hartung","year":"2019","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.msard.2025.106855_bib0028","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420987031","article-title":"Health economics of disease-modifying therapy for multiple sclerosis in the United States","volume":"14","author":"Hartung","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"7","key":"10.1016\/j.msard.2025.106855_bib0001","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamaneurol.2023.1135","article-title":"Population-based estimates for the prevalence of Multiple sclerosis in the United States by race, ethnicity, age, sex, and geographic region","volume":"80","author":"Hittle","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106855_bib0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev.neuro.23.1.155","article-title":"Emotion circuits in the brain","volume":"23","author":"LeDoux","year":"2000","journal-title":"Annu. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.msard.2025.106855_bib0012","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.2196\/ijmr.2993","article-title":"Health literacy association with health behaviors and health care utilization in multiple sclerosis: a cross-sectional study","volume":"3","author":"Marrie","year":"2014","journal-title":"Interact. J. Med. Res."},{"key":"10.1016\/j.msard.2025.106855_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1243589","article-title":"Switching to second line MS disease-modifying therapies is associated with decreased relapse rate","volume":"14","author":"Marriott","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106855_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103920","article-title":"Hiding in plain sight: the magnitude of unused disease modifying therapies in multiple sclerosis and strategies for reducing the economic burden of care","volume":"63","author":"Okuda","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106855_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105041","article-title":"Treatment transitions in neuromyelitis optica spectrum disorder increase risk for disease advancement","volume":"79","author":"Okuda","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106855_bib0004","doi-asserted-by":"crossref","first-page":"103","DOI":"10.36469\/jheor.2024.123336","article-title":"Costs of potential medication wastage due to switching treatment among people with multiple sclerosis","volume":"11","author":"Okuda","year":"2024","journal-title":"J. Health Econ. Outcomes Res."},{"key":"10.1016\/j.msard.2025.106855_bib0034","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-024-12514-x","article-title":"Dimethyl fumarate preserves brainstem and cervical spinal cord integrity in radiologically isolated syndrome","author":"Okuda","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106855_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106009","article-title":"Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: the DELIVER-MS study protocol","volume":"95","author":"Ontaneda","year":"2020","journal-title":"Contemp Clin. Trial."},{"key":"10.1016\/j.msard.2025.106855_bib0008","series-title":"R: A language and Environment For Statistical Computing","year":"2021"},{"issue":"3","key":"10.1016\/j.msard.2025.106855_bib0041","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.beproc.2012.03.017","article-title":"Discounting the freedom to choose: implications for the paradox of choice","volume":"90","author":"Reed","year":"2012","journal-title":"Behav. Proc."},{"issue":"17","key":"10.1016\/j.msard.2025.106855_bib0029","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000201029","article-title":"Disease reactivation after cessation of Disease-modifying therapy in patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Roos","year":"2022","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.msard.2025.106855_bib0017","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1212\/WNL.0000000000004025","article-title":"Racial disparities in neurologic health care access and utilization in the United States","volume":"88","author":"Saadi","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2025.106855_bib0027","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/jamaneurol.2019.2711","article-title":"Trends in prices, market share, and spending on self-administered disease-modifying therapies for multiple sclerosis in Medicare Part D","volume":"76","author":"San-Juan-Rodriguez","year":"2019","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106855_bib0019","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/j.1532-5415.2006.00834.x","article-title":"Ethnic differences in expectations for aging among older adults","volume":"54","author":"Sarkisian","year":"2006","journal-title":"J. Am. Geriatr Soc."},{"issue":"7","key":"10.1016\/j.msard.2025.106855_bib0021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis","volume":"23","author":"Simpson","year":"2021","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.msard.2025.106855_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1274194","article-title":"Predictors of treatment switching in the Big Multiple Sclerosis Data Network","volume":"14","author":"Spelman","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106855_bib0009","unstructured":"Therneau T. A package for survival analysis in R. 2023."},{"issue":"5","key":"10.1016\/j.msard.2025.106855_bib0032","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity-free relapsing multiple sclerosis","volume":"85","author":"University of California","year":"2019","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106855_bib0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1037\/hea0000242","article-title":"Understanding associations among race, socioeconomic status, and health: patterns and prospects","volume":"35","author":"Williams","year":"2016","journal-title":"Health Psychol."},{"issue":"5","key":"10.1016\/j.msard.2025.106855_bib0018","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/ane.12465","article-title":"Illness perception, treatment beliefs, self-esteem, and self-efficacy as correlates of self-management in multiple sclerosis","volume":"133","author":"Wilski","year":"2016","journal-title":"Acta. Neurol. Scand."},{"issue":"9","key":"10.1016\/j.msard.2025.106855_bib0007","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3111\/13696998.2015.1044276","article-title":"Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis","volume":"18","author":"Yermakov","year":"2015","journal-title":"J. Med. Econ."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:37:59Z","timestamp":1784345879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"alternative-id":["S2211034825005978"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106855","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why the disease modifying therapy transition? Investigating the reasons and clinical consequences in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106855","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106855"}}